Protective immunity induced through two calving seasons following administration of live epizootic bovine abortion agent (EBAA) vaccine

IF 1.4 3区农林科学 Q4 IMMUNOLOGY Veterinary immunology and immunopathology Pub Date : 2024-05-03 DOI:10.1016/j.vetimm.2024.110772

Myra T. Blanchard , Mike B. Teglas , Kassidy M. Collins , Mark L. Anderson , Bret R. McNabb , Jeffrey L. Stott

{"title":"Protective immunity induced through two calving seasons following administration of live epizootic bovine abortion agent (EBAA) vaccine","authors":"Myra T. Blanchard , Mike B. Teglas , Kassidy M. Collins , Mark L. Anderson , Bret R. McNabb , Jeffrey L. Stott","doi":"10.1016/j.vetimm.2024.110772","DOIUrl":null,"url":null,"abstract":"<div>A live, infectious vaccine candidate for epizootic bovine abortion, designated EBAA Vaccine, USDA-APHIS Product code #1544.00, has been reported to be both safe and effective. Previous studies established that a single dose of EBAA vaccine administered to cows at potencies of either 2000 or 500 live P. abortibovis-infected murine spleen cells (P.a.-LIC) induced protective immunity for a minimum of 5 months. The current study employed 19 pregnant cows that were challenged with P. abortibovis in their 2nd trimester of gestation; 9 were vaccinated 17.2-months earlier as 1-year-olds with 2000 P.a.-LIC and 10 served as negative controls. Eighty-nine percent of the vaccinates gave birth to healthy calves as compared to 10% of challenge controls. Vaccine efficacy was significant when analyzed by prevented fractions (87.7%; 95% CI=0.4945–0.9781). Serologic data supports previous findings that pregnant cows with detectable P. abortibovis antibodies are immune to P. abortibovis challenge as demonstrated by the birth of healthy calves.</div>","PeriodicalId":23511,"journal":{"name":"Veterinary immunology and immunopathology","volume":"272 ","pages":"Article 110772"},"PeriodicalIF":1.4000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary immunology and immunopathology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165242724000588","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

A live, infectious vaccine candidate for epizootic bovine abortion, designated EBAA Vaccine, USDA-APHIS Product code #1544.00, has been reported to be both safe and effective. Previous studies established that a single dose of EBAA vaccine administered to cows at potencies of either 2000 or 500 live P. abortibovis-infected murine spleen cells (P.a.-LIC) induced protective immunity for a minimum of 5 months. The current study employed 19 pregnant cows that were challenged with P. abortibovis in their 2nd trimester of gestation; 9 were vaccinated 17.2-months earlier as 1-year-olds with 2000 P.a.-LIC and 10 served as negative controls. Eighty-nine percent of the vaccinates gave birth to healthy calves as compared to 10% of challenge controls. Vaccine efficacy was significant when analyzed by prevented fractions (87.7%; 95% CI=0.4945–0.9781). Serologic data supports previous findings that pregnant cows with detectable P. abortibovis antibodies are immune to P. abortibovis challenge as demonstrated by the birth of healthy calves.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在两个产犊季节接种牛流行性流产剂 (EBAA) 活疫苗后产生的保护性免疫力

据报道，一种候选的牛附红细胞体流产传染性活疫苗（EBAA 疫苗，USDA-APHIS 产品代码 #1544.00）既安全又有效。先前的研究证实，给奶牛注射单剂量的 EBAA 疫苗，其效力为 2000 或 500 个受阿博提包虫病感染的小鼠脾脏活细胞 (P.a.-LIC)，可诱导至少 5 个月的保护性免疫。目前的研究使用了 19 头妊娠母牛，这些母牛在妊娠的后三个月受到了阿波尔提巴氏杆菌的挑战；其中 9 头在 17.2 个月前接种了 2000 株 P.a.-LIC 疫苗，当时它们才 1 岁，另外 10 头作为阴性对照。89% 的接种者产下了健康的小牛，而 10% 的阴性对照者产下了健康的小牛。按预防分数分析，疫苗效果显著（87.7%；95% CI=0.4945-0.9781）。血清学数据支持之前的研究结果，即检测到阿波尔提巴虫卵抗体的怀孕母牛对阿波尔提巴虫卵挑战免疫，健康小牛的出生证明了这一点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Veterinary immunology and immunopathology 农林科学-免疫学

CiteScore

3.40

自引率

5.60%

发文量

审稿时长

70 days

期刊介绍： The journal reports basic, comparative and clinical immunology as they pertain to the animal species designated here: livestock, poultry, and fish species that are major food animals and companion animals such as cats, dogs, horses and camels, and wildlife species that act as reservoirs for food, companion or human infectious diseases, or as models for human disease. Rodent models of infectious diseases that are of importance in the animal species indicated above,when the disease requires a level of containment that is not readily available for larger animal experimentation (ABSL3), will be considered. Papers on rabbits, lizards, guinea pigs, badgers, armadillos, elephants, antelope, and buffalo will be reviewed if the research advances our fundamental understanding of immunology, or if they act as a reservoir of infectious disease for the primary animal species designated above, or for humans. Manuscripts employing other species will be reviewed if justified as fitting into the categories above. The following topics are appropriate: biology of cells and mechanisms of the immune system, immunochemistry, immunodeficiencies, immunodiagnosis, immunogenetics, immunopathology, immunology of infectious disease and tumors, immunoprophylaxis including vaccine development and delivery, immunological aspects of pregnancy including passive immunity, autoimmuity, neuroimmunology, and transplanatation immunology. Manuscripts that describe new genes and development of tools such as monoclonal antibodies are also of interest when part of a larger biological study. Studies employing extracts or constituents (plant extracts, feed additives or microbiome) must be sufficiently defined to be reproduced in other laboratories and also provide evidence for possible mechanisms and not simply show an effect on the immune system.